Theon International reiterates FY26 revenue guidance of €570-600m

scanx
Reviewed by
Radhika SScanX News Team
Key Highlights

Theon International has reiterated its FY26 revenue guidance of €570-600m with mid-20s adjusted EBIT margins. Edison’s valuation stands at €35.3 per share, slightly down from €36.4. The company is expanding into platform-based optronics, supported by M&A and rising defence demand.

powered bylight_fuzz_icon
45850921

*this image is generated using AI for illustrative purposes only.

Theon International has reaffirmed its revenue and margin guidance for FY26, projecting revenues between €570m and €600m with adjusted EBIT margins in the mid-20s. The company, a developer of night vision and thermal imaging systems, issued the update in its Q126 trading report. Edison’s valuation model now suggests a price of €35.3 per share, broadly unchanged from its previous estimate of €36.4.

Theon operates across 72 countries, supplying military and security sectors. Having established a leading position in man-portable night vision, the company is expanding into platform-based optronics and digital man-portable products. This growth is supported by an active M&A programme and structurally rising defence demand.

Edison’s report highlights Theon’s strategic shift and its ability to maintain guidance despite market fluctuations. The research firm notes that the company’s broadening product portfolio and global footprint position it well for sustained growth.

Financial Outlook

Theon’s Q126 trading update included the following key projections:

Metric Guidance
FY26 Revenue €570-600m
Adjusted EBIT Margins Mid-20s
Edison Valuation €35.3 per share

The company’s focus on high-margin defence contracts and expansion into new product categories underpins its confidence in the mid-term targets. Edison’s valuation reflects a steady outlook, with minimal adjustment from the prior estimate.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific acquisition targets is Theon pursuing to support its expansion into platform-based optronics?

How will the shift to digital man-portable products impact R&D spending and margin profiles in the near term?

Which geographic regions are expected to drive the strongest demand growth given Theon's presence in 72 countries?

like15
dislike

Theon International Plc to host investor webcast ahead of Q2 results

scanx
Reviewed by
Naman SScanX News Team
Key Highlights

Theon International Plc will host an investor webcast on July 9, 2026, to discuss recent developments, including the €300 million acquisition of SAS Stéropès, ahead of its Q2 results on July 27, 2026. The session will be led by Deputy CEO Philipe Mennicken and CFO Dimitris Parthenis, featuring a live Q&A.

powered bylight_fuzz_icon
44998784

*this image is generated using AI for illustrative purposes only.

Theon International Plc will host a follow-up webcast session via the Investor Meet Company platform on Thursday, 09 July 2026, at 11:00am UK-time / 1:00pm Eastern European-time. The session aims to engage with existing and potential investors ahead of the upcoming Q2 results announcement on 27 July 2026, after market close. The webcast will provide an update on recent developments, financial profile, business dynamics, guidance, and strategic initiatives, including the recent agreement to acquire SAS Stéropès, the holding company of SAS HGH Systèmes Infrarouges (HGH), for an enterprise value of approximately €300 million.

The webcast will be hosted by Philipe Mennicken, Deputy CEO and Business Development Director, and Dimitris Parthenis, CFO of Theon International Plc. They will discuss the company's strategic developments and recap its guidance and targets. The session will feature a live Q&A and is open to all existing and potential investors as well as wider market participants.

Investors can sign up for the Investor Meet Company platform for free to attend the event. Those already following Theon International Plc on the platform will automatically receive an invitation. Questions can be submitted ahead of the event via the platform dashboard until 9:00am UK-time / 11:00am Eastern European-time on 09 July 2026, or during the live session.

Key Event Details

Event Detail Information
Event Date 09 July 2026
Time (UK) 11:00am
Time (EET) 1:00pm
Q2 Results Date 27 July 2026
Acquisition Target SAS Stéropès (HGH)
Enterprise Value €300 million

Theon International Plc develops and manufactures night vision and thermal imaging systems for defense and security applications. The company has been listed on Euronext Amsterdam (AMS: THEON) since February 2024. In 2025, Theon Group won a procurement tender for over 100,000 Night Vision Goggles for the Belgian and German Armed Forces, valued at approximately €1 billion.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How will the €300 million acquisition of HGH impact Theon's revenue diversification and market positioning in the thermal imaging sector?

What synergies are expected from the integration of HGH, and how will they contribute to Theon's long-term growth strategy?

Will the acquisition affect Theon's financial guidance or capital allocation plans for the remainder of 2026?

like16
dislike

More News on Theon International Plc